## **Core Concept**
Acute Myeloid Leukemia (AML) is a heterogeneous group of diseases characterized by the clonal expansion of myeloid blasts in the bone marrow and peripheral blood. The prognosis in AML is influenced by various factors, including cytogenetic abnormalities, molecular genetic mutations, and the patient's age and performance status.

## **Why the Correct Answer is Right**
The correct answer, , is associated with a poor prognosis in AML patients. This is because complex cytogenetic abnormalities often indicate a higher risk of treatment failure and shorter overall survival. These abnormalities can lead to a more aggressive disease course and reduced responsiveness to chemotherapy.

## **Why Each Wrong Option is Incorrect**
* **Option A:** is not specifically mentioned as having a poor prognosis compared to .
* **Option B:** Some studies suggest that certain translocations like t(8;21) and inv(16) are associated with a favorable prognosis in AML, especially when treated with targeted therapies.
* **Option C:** While certain molecular markers like FLT3-ITD and NPM1 mutation status are important for prognosis, the question specifically mentions cytogenetic abnormalities.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl in AML is that cytogenetic and molecular profiling are crucial for determining the prognosis and guiding treatment decisions. Complex karyotypes, like , are generally associated with an adverse prognosis.

## **Correct Answer:** .